
HANSA
BIOPHARMA
TD Cowen Healthcare
Conference 2024
Boston, March 4-5
Søren Tulstrup
President & CEO

Forward-looking statements

This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will occur in the future. Some of these forward-looking statements, by their nature, could have an impact on Hansa Biopharma's business, financial condition and results of operations [or that of its parent, affiliate, or subsidiary companies]. Terms such as "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially from those projected, whether expressly or impliedly, in a forward-looking statement or affect the extent to which a particular projection is realized. Such factors may include, but are not limited to, changes in implementation of Hansa Biopharma's strategy and its ability to further grow; risks and uncertainties associated with the development and/or approval of Hansa Biopharma's product candidates; ongoing clinical trials and expected trial results; the ability to commercialize imlifidase if approved; changes in legal or regulatory frameworks, requirements, or standards; technology changes and new products in Hansa Biopharma's potential market and industry; the ability to develop new products and enhance existing products; the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors.

The factors set forth above are not exhaustive and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment, and it is not possible to predict all factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.

Hansa Biopharma expressly disclaims any obligation to update or revise any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or otherwise, and disclaims any express or implied representations or warranties that may arise from any forward-looking statements. You should not rely upon these forward-looking statements after the date of this presentation.

HANSA BIOPHARMA

Hansa Biopharma today

A successful track record and a promising future…

A validated technology

- Commercial stage biotech company
- Approval in kidney transplantation (EU)
- Market Access in 14 European markets
- PoC in autoimmune diseases
- Three partnerships in gene therapy

Broad clinical pipeline



- Imlifidase being investigated in seven ongoing clinical programs in transplantation and autoimmune disease
- Ongoing clinical study in gene therapy
- HNSA-5487: Encouraging data from phase I first-in-human trial

Skilled and experienced team

- A high-performance organization with 20 years on average in life science
- Purpose driven culture
- Headquartered in Lund, Sweden (168 employees Dec'23)
- Operations in both EU and the US

Financial position

- Hansa is financed into 2025
- Market cap (USD): ~185m (Feb. 2023)
- Listed on Nasdaq Stockholm
- 20,000 shareholders
- Foreign ownership make up ~43%

3

Key milestones achieved during the last 12 months



Imlifidase

a novel approach to eliminate pathogenic IgG

Origins from a bacteria *Streptococcus pyogenes*

- Species of Gram-positive, spherical bacteria in the genus *Streptococcus*
- Usually known from causing a strep throat infection



A unique IgG antibody-cleaving enzyme

- Interacts with Fc-part of IgG with extremely high specificity
- Cleaves IgG at the hinge region, generating one F(ab')2 fragment and one homo-dimeric Fc-fragment



Inactivates IgG in 2-6 hours

- Rapid onset of action that inactivates IgG below detectable level in 2-6 hours
- IgG antibody-free window for approximately one week



Potential indication universe



*) The EU Commission has granted conditional approval for imlifidase in highly sensitized kidney transplant patients.
**) In the US a new study has commenced targeting a BLA filing in 2025

Broad clinical pipeline in transplantation, autoimmune diseases, and gene therapy

Project	Indication	Research/ Preclinical	Phase 1	Phase 2	Phase 3	Marketing Authorization	Marketed	Partner	Next Anticipated Milestone
Imlifidase	EU: Kidney transplantation in highly sensitized patients[1,2]								EU: Additional agreements around reimbursement / Post approval study to be completed by 2025
	U.S. "ConfIdeS": Kidney transplantation in highly sensitized patients[1,2]								Completion of randomization (64 patients) mid 2024
	GOOD-IDES-02: Anti-GBM antibody disease								Complete enrollment (50 patients)
	16-HMedIdes-12: Active Antibody Mediated Rejection (AMR)								Publication in peer-reviewed journal
	15-HMedIdeS-09: Guillain-Barré Syndrome (GBS)								Comparative efficacy analysis 2024
	Investigator-initiated trial in ANCA-associated vasculitis[3]								Complete enrollment (10 patients)
	SRP-9001-104: Pre-treatment ahead of gene therapy in Duchenne Muscular Dystrophy (DMD)		Phase 1b					**Sarepta Therapeutics**	Completion of enrolmen
	Pre-treatment ahead of gene therapy in Limb-Girdle Muscular Dystrophy (LGMD)							**Sarepta Therapeutics**	Preclinical research
	Pre-treatment ahead of gene therapy in Pompe disease							**AskBio**	Preclinical research
	Pre-treatment ahead of gene therapy in Crigler-Najjar syndrome							**Genethon**	Commence clinical study
HNSA-5487	NICE-01 phase 1: HNSA-5487 – Lead candidate from the NiceR program								Further analysis around endpoints from Phase 1 to be completed in 2024 incl. selection of lead indication

Completed | Ongoing | Planned | Post approval study running in parallel with commercial launch

[1] Results from the Phase 1 study have been published, Winstedt et al. (2015) PLOS ONE 10(7)
[2] Lorant et al., American Journal of Transplantation and 03+04 studies (Jordan et al., New England Journal of Medicine)
[3] Investigator-initiated study by Dr. Adrian Schreiber and Dr. Philipp Enghard, at Charité Universitätsmedizin, Berlin, Germany

Imlifidase in kidney transplantation



HANSA BIOPHARMA

Idefirix® is the first and only approved drug in Europe for desensitization of highly sensitized kidney transplant patients

Inability to match or effectively desensitize patients remains a barrier for transplantation in highly sensitized patients.
Between 80,000 and 100,000 kidney transplant patients are waiting for a new kidney in both Europe and the U.S.

Low complexity transplants ← Calculated Panel Reactive Antibodies (cPRA) is a measure for HLA-sensitization → High complexity transplants

~70% of patients[1,2]	15-20% of patients[1,2]	10-15% of patients[1,2]
Non or less sensitized (cPRA < 20%)	Moderately sensitized (20% < cPRA < 80%)	Highly sensitized (cPRA > 80%)

Causes of sensitization include

Pregnancy

Blood transfusion

Previous transplantations

Addressable market (annually)

4,000-6,000

split across Europe and the US

Patients that are likely to be transplanted with a compatible donor

Patients unlikely to be transplanted under current prioritization programs

idefirix® imlifidase

[1] EDQM. (2020). International figures on donation and Transplantation 2019
[2] SRTR Database and individual assessments of allocation systems

Market Access obtained in 14 markets covering markets with 3/4 of transplant volumes in Europe

Positive reimbursement decision received in Slovenia as of February 1, 2024



[1] Annual kidney transplantations 2022. Transplantation data is from Global Observatory on Donation and Transplantation, https://www.transplant-observatory.org/ [Accessed 2023-07-10]

[2] A positive recommendation for pricing and reimbursement of Idefirix® in Spain was published on February 6, 2023, https://www.sanidad.gob.es/profesionales/farmacia/pdf/20230202_ACUERDOS_CIPM_230.pdf

Potential to disrupt transplantation care in the U.S. with imlifidase

ConfIdeS phase 3 trial will further advance potential for imlifidase to address unmet need in desensitization

U.S. ConfIdeS

Phase 3

- Continue enrollment beyond 64 patients
- Currently 104 patients screened and enrolled
- More than 2/3 of targeted patients randomized
- Expansion from 17 to 25 site to accelerate randomization
- Randomization expected to complete mid-2024
- BLA filing in 2025

Involved ConfIdeS sites cover more than 20% of total transplantation volumes in the U.S[1]



[1]Organ Procurement & Transplantation Network, OPTN (2023)

Clinical development programs

HANSA BIOPHARMA

Autoimmune attacks

A result of when the body's immune system by mistake damages its own tissue

Blood
Autoimmune hemolytic anemia,
Immune thrombocytopenia

GI tract
Crohn's disease



Nerves
Guillain-Barré syndrome,
Myasthenia gravis

Lung
Wegner's granulomatosis





Over 100 different types of Autoimmune disorders

Skin
Psoriasis, Pemphigus



Brain
Multiple sclerosis,
Neuromyelitis optica

Thyroid
Hashimoto's disease,
Graves' disease



Kidney
Anti-GBM disease



Bone and muscle
Rheumatoid arthritis,
Dermatomyositis+ 32

Hansa's antibody cleaving enzyme technology

may have relevance in several autoimmune diseases where IgG plays an important role in the pathogenesis

Rapidly progressive glomerulonephritis

~1 000 patients*[1]

- Anti-GBM
- Lupus nephritis ~35 000*[2]
- ANCA-associated vasculitis ~20 000*[3]

Neurological disorders

- Myasthenia gravis ~210 000*[4]
- NMO ~20 000*[7]
- CIDP ~55 000*[6]
- GBS

~10 000 patients*[5]

Skin disorders

<1 000 patients*[8]

- EBA
- Pemphigus vulgaris ~40 000*[9]

Blood disorders

~1 000* patients[13]

- AHA
- WAHA ~95 000*[11]
- APS ~350 000*[12]
- HIT 0.1–5% of patients receiving therapeutic dose of heparin[14]
- ITP ~75 000*[10]

■ Clinical programs

□ Potential autoimmune indications (currently not pursued)

*Total disease populations in EU & US, based on prevalence and population data

CIDP: Chronic inflammatory demyelinating polyradiculoneuropathy
NMO: Neuromyelitis optica
EBA: Epidermolysis bullosa acquisita
ITP: Immune thrombocytopenia
WAHA: Warm antibody hemolytic anemia
APS: Antiphospholipid syndrome
AHA: acquired hemophilia A
HIT: Heparin-induced thrombocytopenia

[1]DeVrieze, B.W. and Hurley, J.A. *Goodpasture Syndrome*. StatPearls Publishing, Jan 2021. https://www.ncbi.nlm.nih.gov/books/NBK459291/ [accessed 2021-03-29]
[2]Patel, M et al. *The Prevalence and Incidence of Biopsy-Proven Lupus Nephritis in the UK*. Arthritis & Rheumatism, 2006.
[3]Berti A, Cornec D, Crowson CS, Specks U, Matteson EL. *The Epidemiology of ANCA Associated Vasculitis in the U.S.: A 20 Year Population Based Study*. Arthritis Rheumatol. 2017;69.
[4]*Myasthenia Gravis*. National Organization for Rare Disorders, https://rarediseases.org/rare-diseases/myasthenia-gravis/ [accessed 2021-03-29]
[5]*Guillain-Barré syndrome*. Orpha.net, https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=GB&Expert=2103 [accessed 2021-03-29]
[6]*Chronic Inflammatory Demyelinating Polyneuropathy: Considerations for Diagnosis, Management, and Population Health*. The American Journal of Managed Care. https://www.ajmc.com/view/chronic-inflammatory-demyelinating-polyneuropathy-considerations-for-diagnosis-management-and-population-health [accessed 2021-03-29]
[7]Marrie, R.A. *The Incidence and Prevalence of Neuromyelitis Optica*. International Journal of MS Care, 2013 Fall: 113-118
[8]Mehren, C.R. and Gniadecki, R. *Epidermolysis bullosa acquisita: current diagnosis and therapy*. Dermatol Reports, 2011-10-05
[9]Wertenteil, S. et al. Prevalence *Estimates for Pemphigus in the United States*. JAMA Dermatol, May 2019: 627-629.
[10]*Immune Thrombocytopenia*. National Organization for Rare Disorders. https://rarediseases.org/rare-diseases/immune-thrombocytopenia// [accessed 2021-03-29]
[11]*Warm Autoimmune Hemolytic Anemia*. National Organization for Rare Disorders. https://rarediseases.org/rare-diseases/warm-autoimmune-hemolytic-anemia/ [accessed 2021-03-29]
[12]Litvinova, E. et al. *Prevalence and Significance of Non-conventional Antiphospholipid Antibodies in Patients With Clinical APS Criteria*. Frontiers in Immunology, 2018-12-14.
[13]NORD, Acquired Hemophilia [accessed 2022-10-17], available at https://rarediseases.org/rare-diseases/acquired-hemophilia/
[14]Hogan M, Berger JS. Heparin-induced thrombocytopenia (HIT): Review of incidence, diagnosis, and management. Vascular Medicine. 2020;25(2):160-173. doi:10.1177/1358863X19898253

Gene Therapy



HANSA BIOPHARMA

Neutralizing antibodies (Nabs) are immunological barriers in gene therapy; imlifidase may potentially eliminate Nabs

Between approximately 5%-70%[1,2] of patients considered for gene therapy treatment carry neutralizing anti-AAV antibodies forming a barrier for treatment eligibility

1 Antibodies prevent effective transfer of healthy gene sequence and can be a safety concern



2 Imlifidase is a unique IgG antibody-cleaving enzyme that cleaves IgG at the hinge region with extremely high specificity



3 The idea is to eliminate the neutralizing antibodies as a pre-treatment to enable gene therapy



[1] Boutin (2010)
[2] Kruzik (2019)

Systemic gene therapy is an emerging opportunity

with a focus on the potential to correct diseases causing genes in rare monogenic diseases

Rare monogenic diseases
From hundreds of patients to thousands of patients

Size of indication (US & EU)

Preclinical programs with Sarepta, AskBio and Genethon
Ongoing clinical study with Sarepta
Potential gene therapy indications (currently not pursued)

AAV5 etc
NAbs: up to ~10%
DM1
+100,000[1]
Astellas, EditForce, Locanabio

AAV5 etc
NAbs: up to ~30%
PKU
~25,000[5]
Biomarin, Homology Medicines

AAV9 etc
NAbs: up to ~30%
Wilson
~40,000[3]
Vivet, Ultragenyx

AAV5 etc
NAbs: up to ~10%
HAE
~8,000[4]
BioMarin

AAV9 etc
NAbs: up to ~30%
Gaucher
~18,000[2]
Freeline, Eli Lilly

AAV5 etc
NAbs: up to ~10%
Fabry
~9,000[6]
uniQure, Sangamo

AAVrh74 etc
NAbs: up to ~20%
Limb-Girdle
~20,000[7]
Sarepta, AskBio, Atamyo

AAV8 etc
NAbs: up to ~60%
Pompe
~10,000[8]
Spark, AskBio, Astellas

AAV9 etc
NAbs: up to ~30%
Hunter
~6,000[10]
REGENXBIO, Homology Medicines

AAV8 etc
NAbs: up to ~40%
Crigler -Najjar
~600[9]
Genethon, LogicBio

AAV8 etc
NAbs: up to ~60%
OTC-deficiency
~20,000[11]
Ultragenyx

AAV5, AAV6 etc
NAbs: up to ~45%
Hemophilia B
~14,000[13]
CSL, Pfizer, Belief, UniQure

AAVrh74, AAV9 etc NAbs: up to ~30%
Duchenne
~20,000[12]
Sarepta, Pfizer, Astellas

AAV9 etc
NAbs: up to ~30%
SMA
~30,000[14]
Novartis

AAV5, AAV6 etc
NAbs: up to ~45%
Hemophilia A
~40,000[13]
BioMarin, Spark uniQure, Pfizer

Late Preclinical — **Clinical** — **Market**

Numbers are estimated based on population and prevalence

1. Rarediseases.org, https://rarediseases.org/rare-diseases/dystrophy-myotonic/ [Accessed 2023-06-26]
2. Medlineplus.gov, https://medlineplus.gov/genetics/condition/gaucher-disease/#frequency [Accessed 2023-06-20
3. Sandahl TD, Laursen TL, Munk DE, Vilstrup H, Weiss KH, Ott P. The Prevalence of Wilson's Disease: An Update. Hepatology. 2020 Feb;71(2):722-732. doi: 10.1002/hep.30911. Epub 2020 Jan 31. PMID: 31449670.
4. Ghazi A, Grant JA. Hereditary angioedema: epidemiology, management, and role of icatibant. Biologics. 2013;7:103-13. doi: 10.2147/BTT.S27566. Epub 2013 May 3. PMID: 23662043; PMCID: PMC3647445.
5. Hillert A, et. al. The Genetic Landscape and Epidemiology of Phenylketonuria. Am J Hum Genet. 2020 Aug 6;107(2):234-250. doi: 10.1016/j.ajhg.2020.06.006. Epub 2020 Jul 14. PMID: 32668217; PMCID: PMC7413859.
6. Medlineplus.gov, https://medlineplus.gov/genetics/condition/fabry-disease/#frequency [Accessed: 2023-07-12]
7. Liang, WC., Jong, YJ., Wang, CH. et al. Clinical, pathological, imaging, and genetic characterization in a Taiwanese cohort with limb-girdle muscular dystrophy. Orphanet J Rare Dis 15, 160 (2020). https://doi.org/10.1186/s13023-020-01445-1
8. Rarediseases.org, https://rarediseases.org/rare-diseases/pompe-disease/ [Accessed 2023-07-12]
9. Genethon.com, https://www.genethon.com/our-projects/rare-neuro-syndromic/ [Accessed 2023-06-15]
10. Gajula P, Ramalingam K, Bhadrashetty D. A rare case of mucopolysaccharidosis: Hunter syndrome. J Nat Sci Biol Med. 2012 Jan;3(1):97-100. doi: 10.4103/0976-9668.95984
11. Rarediseases.org, https://rarediseases.org/rare-diseases/ornithine-transcarbamylase-deficiency/ [Accessed 2023-07-12]
12. Crisafulli S. et. Al. Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. Orphanet J Rare Dis. 2020 Jun 5;15(1):141. doi: 10.1186/s13023-020-01430-8. PMID: 32503598; PMCID: PMC7275323.
13. GlobalData [Accessed 2023-12-15]
14. Verhaart, I.E.C., Robertson, A., Wilson, I.J. et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy – a literature review. Orphanet J Rare Dis 12, 124 (2017). https://doi.org/10.1186/s13023-017-0671-8

Global exclusive agreements with three partners in gene therapy

To develop and promote imlifidase as pre-treatment ahead of gene therapy in select indications

Partner	Access to key resources	Indication exclusivity	Collaborative research, development and commercialization
SAREPTA THERAPEUTICS	▪ World leader within gene therapy targeted at muscular dystrophies ▪ Pre-clinical and clinical plan ▪ Regulatory ▪ Promotion ▪ FDA approval in 4–5-year-old kids suffering with DMD	**Duchenne Muscular Dystrophy (DMD)** 1/3,500 to 5,000 male births worldwide	Antibody cleaving enzyme technology ✓ → Preclinical Development ✓ → Initiated Clinical Development → Regulatory Approvals → Commercialization
		Limb-Girdle Muscular Dystrophy Global prevalence of ~1.6 per 100k individuals	Antibody cleaving enzyme technology ✓ → Preclinical Development → Clinical Development → Regulatory Approvals → Commercialization
AskBio	▪ Early innovator in gene therapy ▪ Conducts pre-clinical and clinical trials (Phase 1/2)	**Pompe disease** Approximate incidence is 1 per 40,000 births, or ~200 per year in the US + EU	Antibody cleaving enzyme technology ✓ → Preclinical Development → Clinical Development Phase 1/2 study (feasibility)
GENETHON CURE THROUGH INNOVATION	▪ A pioneer in the discovery and development of gene therapies ▪ Conducts pre-clinical and clinical trials (Phase 1/2)	**Crigler-Najjar syndrome** Approximately incidence is 0.6-1 case per one million people or 600 patients in Europe and the U.S	Antibody cleaving enzyme technology ✓ → Preclinical Development → Clinical Development Phase 1/2 study (feasibility)

Exclusive option for AskBio to negotiate a potential full development and commercialization agreement

The initial agreement is focused on research and development

The companies will consider a subsequent agreement for commercialization at a later stage

Next generation enzymes



Advancing HNSA 5487 – a high potential next-gen enzyme for repeat dosing

HNSA-5487

- Engineered for lower immunogenicity
- Short and long-term interval dosing
- Broad range of indications (prolonged or intermittent IgG-free window)

Broaden the IgG free window

Rapidly cleaves IgG and could potentially create a longer IgG-low period

Address unmet need in autoimmune disease

Powerful 5487 IgG cleaving in combination with humoral inhibitor could result in greater control of disease in variety of autoimmune diseases

Enable re-dosing in gene therapy

Could provide solutions to enable re-dosing in AAV gene therapy and prolonged dosing of oncolytic viruses

Potential indication landscape for HNSA-5487 and reasons to believe



First in Human Study Results

- ✓ Administration was safe and well tolerated
- ✓ PD showed a fast and complete cleavage of IgG to $F(ab')_2$ and Fc-fragments with ascending doses; PK in line with expectations
- ✓ Further analysis around endpoints and immunogenicity to be completed in 2024 incl. selection of lead indication

Key strategic priorities

Commercialize Idefirix® in first indication and markets

1

- Successfully launch Idefirix® in Europe
- Secure FDA approval and launch Idefirix® in the U.S.
- Geographic expansion

Advance our ongoing clinical programs

2

- Achieve approval/ usage of imlifidase in follow-on indications
- Broaden the Idefirix® label beyond kidney transplantation

Expand our IgG-cleaving enzyme technology

3

- Expand IgG-cleaving enzyme technology platform into gene therapy
- Develop next gen IgG-cleaving enzymes for repeat usage


HANSA
BIOPHARMA

2023 achievements and upcoming milestones 2024/25

2023

Q4 2023

- ✓ **HNSA-5487 (Lead NiceR candidate):** High-level data readout from Phase 1
- ✓ **Long-term follow-up (Kidney tx):** 5-year data readout
- ✓ **GBS Phase 2:** First data readout
- ✓ **AMR Phase 2:** Full data readout
- ✓ **Sarepta DMD pre-treatment Phase 1b:** Commence clinical study

2024

- **GBS Phase 2:** Outcome of comparative efficacy analysis
- **Genethon Crigler-Najjar Phase 1/2:** Initiate clinical study with imlifidase prior to GNT-0003
- **HNSA-5487 (Lead NiceR candidate):** Further analysis around endpoints to be completed in 2024 incl. lead indication
- **U.S. ConfIdeS (Kidney tx) Phase 3:** Complete randomization
- **Sarepta imlifidase in phase 1b in DMD:** First high level data read-out from phase 1b

2025

- **U.S. ConfIdeS (Kidney tx) Phase 3:** BLA submission
- **Anti-GBM disease Phase 3:** Complete enrolment

Contact our Investor Relations and Corporate Affairs team

Contact

Klaus Sindahl

VP, Head of Investor Relations

Mobile: +46 (0) 709-298 269

Email: klaus.sindahl@hansabiopharma.com

Stephanie Kenney

VP, Global Corporate Affairs

Mobile: +1 (484) 319 2802

E-mail: stephanie.kenney@hansabiopharma.com

Calendar and events

March 4-5, 2024 TD Cowen Healthcare Conference, Boston

March 6, 2024 Life Sciencedagen, Sahlgrenska University Hospital, Gothenburg

Mar 20, 2024 Annual Report 2023

April 8-11, 2024 Needham Healthcare Conference (virtual)

April 16-17, 2024 Van Lanschot Kempen Life Science Conference, Amsterdam

Apr 18, 2024 Interim Report for January-March 2024

June 27, 2024 2024 Annual General Meeting

July 18, 2024 Half-year Report January-June 2024

Oct 24, 2024 Interim Report for January-September 2024